Skip to content

Study of the G protein-biased µ-opioid receptor agonist oliceridine for the management of acute pain after lumbar interbody fusion surgery

Study of the G protein-biased µ-opioid receptor agonist oliceridine for the management of acute pain after lumbar interbody fusion surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128047
Enrollment
Unknown
Registered
2026-07-13
Start date
2026-07-15
Completion date
Unknown
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pain after lumbar interbody fusion surgery

Interventions

sufentanil group:Sufentanil in the postoperative PCIA pump
oliceridine group:oliceridine in the postoperative PCIA pump

Sponsors

Zhongda Hospital, Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. ASA classification: grades I - III; 2. Age 18 - 75 years old; 3. Scheduled for elective general anesthesia for the first time for one- or two-level posterior lumbar interbody fusion; 4. Intention to use postoperative PCIA pump.

Exclusion criteria

Exclusion criteria: 1. Psychiatric disorders; 2. Preoperative cognitive impairment or communication disorders; 3. Body weight 35 kg/m^2; 4. Pregnancy or lactation; 5. History of opioid allergy; 6. Daily use of > 15 mg oral morphine equivalent within the previous 3 months, or alcohol/substance abuse; 7. Chronic non-steroidal anti-inflammatory drug (NSAID) therapy (daily use for > 2 weeks within 6 months before surgery); 8. Hepatic or renal dysfunction; 9. Diagnosed or suspected sleep apnea, or requirement for home oxygen therapy; 10. Refusal to participate in this study.

Design outcomes

Primary

MeasureTime frame
QoR-15 score at 24 h postoperatively;

Secondary

MeasureTime frame
QoR-15 scores at 1 day before surgery and 48 h postoperatively.;NRS pain scores at rest and during movement at 2, 6, 12, 24, and 48 h postoperatively.;Time to the first PCA demand (defined as the time from the end of surgery to the patient's first PCA button press).;Total number of PCA demands and successful PCA demands during the first 24 and 48 h after surgery.;Analgesic consumption from the PCA pump during the first 24 and 48 h after surgery.;Severity and incidence of postoperative nausea and/or vomiting (PONV) during the first 48 h after surgery.;Number of rescue antiemetic treatments, cumulative rescue antiemetic dose, and proportion of patients requiring rescue antiemetic therapy during the first 48 h after surgery.;Time to first flatus after surgery.;Time to first bowel movement after surgery;Time to first ambulation after surgery.;Incidence of adverse events within 48 h after surgery, including sedation, dizziness, pruritus, urinary retention, and respiratory depression.;Patient satisfaction with PCA analgesia;Length of postoperative hospital stay;

Countries

China

Contacts

Public ContactQiu Lili

Zhongda Hospital, Southeast University

qiulili915@163.com+86 182 0518 8563

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026